SCHEMBL4520487

SCHEMBL4520487

Cc1cc(Br)ccc1S(=O)(=O)NCCNc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
ALOX12 P18054 2/20 0.45
POLB P06746 1/20 0.45
HPGD P15428 1/20 0.45
GFER P55789 1/20 0.45
LMNA P02545 1/20 0.43
KMT2A Q03164 3/20 0.41
MEN1 O00255 1/20 0.41
GPR27 Q9NS67 1/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
MEP1B Q16820 1/20 0.40
GAA P10253 1/20 0.39
SFRP1 Q8N474 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4521279 0.80 TDP1 (0.64) CA1CA2ALDH1A1POLBLMNA
SCHEMBL5269149 0.79 CA1 (0.59) CA1CA2ALDH1A1MAPTALOX12
SCHEMBL4506927 0.79 KMT2A (0.59) CA1CA2ALDH1A1LMNAKMT2A
SCHEMBL120177 0.79 LMNA (0.66) CA1CA2MAPTPOLBLMNA
SCHEMBL30309662 0.79 CA1 (0.61) CA1CA2ALDH1A1HPGDKMT2A
SCHEMBL16735334 0.79 CA1 (0.61) CA1CA2ALDH1A1HPGDKMT2A
SCHEMBL19869958 0.77 GAA (0.61) CA1CA2ALDH1A1POLBKMT2A
SCHEMBL16118202 0.77 CA1 (0.59) CA1CA2ALDH1A1MAPTALOX12
SCHEMBL16098346 0.76 CA1 (0.66) CA1CA2ALDH1A1LMNASMN1; SMN2
SCHEMBL4516684 0.74 L3MBTL1 (0.67) ALDH1A1MAPTALOX12POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
CN-101094832-A Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases ASTRAZENECA AB (SE) 2007-12-26 CN disclosed
EP-1807391-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AstraZeneca AB (SE) 2007-07-18 EP disclosed
WO-2006046916-A1 NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 CA1 2460/4885CA2 1356/4885ALDH1A1 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.